TW200500068A - Crystalline therapeutic agent - Google Patents
Crystalline therapeutic agentInfo
- Publication number
- TW200500068A TW200500068A TW093103036A TW93103036A TW200500068A TW 200500068 A TW200500068 A TW 200500068A TW 093103036 A TW093103036 A TW 093103036A TW 93103036 A TW93103036 A TW 93103036A TW 200500068 A TW200500068 A TW 200500068A
- Authority
- TW
- Taiwan
- Prior art keywords
- therapeutic agent
- crystalline therapeutic
- crystalline
- sildenafil
- citrate
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229960002639 sildenafil citrate Drugs 0.000 abstract 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0303097A GB0303097D0 (en) | 2003-02-11 | 2003-02-11 | Crystalline therapeutic agent |
| GB0321309A GB0321309D0 (en) | 2003-09-11 | 2003-09-11 | Crystalline therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200500068A true TW200500068A (en) | 2005-01-01 |
Family
ID=32870944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093103036A TW200500068A (en) | 2003-02-11 | 2004-02-10 | Crystalline therapeutic agent |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR043143A1 (zh) |
| TW (1) | TW200500068A (zh) |
| WO (1) | WO2004072079A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300979T3 (es) * | 2004-01-05 | 2008-06-16 | Teva Pharmaceutical Industries Ltd. | Procedimiento para la produccion de sildenafilo base y de su sal citrato. |
| EP1779852A3 (en) * | 2004-01-05 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Processes for the production of sildenafil base and citrate salt |
| AU2006237300B2 (en) | 2005-04-19 | 2011-10-13 | Takeda Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| CN104940154A (zh) * | 2015-07-23 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗泌尿外科疾病的药物枸橼酸西地那非组合物片剂 |
| CN104940166A (zh) * | 2015-07-23 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗男性阳痿的药物枸橼酸西地那非组合物胶囊 |
| CN105147690A (zh) * | 2015-09-28 | 2015-12-16 | 青岛华之草医药科技有限公司 | 一种治疗泌尿外科类疾病的药物枸橼酸西地那非组合物片剂 |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| EP4294819A4 (en) | 2021-02-18 | 2024-12-18 | Praxis Precision Medicines, Inc. | GABA-A POSITIVE ALLOSTERIC MODULATOR HEMI-CITRATE SALTS AND CORRESPONDING CRYSTALLINE FORM |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB9822238D0 (en) * | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| US6420557B1 (en) * | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
| WO2002010171A1 (en) * | 2000-07-28 | 2002-02-07 | Pfizer Limited | Crystalline therapeutic agent |
-
2004
- 2004-02-05 WO PCT/IB2004/000315 patent/WO2004072079A1/en not_active Ceased
- 2004-02-10 AR ARP040100410A patent/AR043143A1/es unknown
- 2004-02-10 TW TW093103036A patent/TW200500068A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004072079A1 (en) | 2004-08-26 |
| AR043143A1 (es) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60112974D1 (en) | Carbolinderivate | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| MY134892A (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
| GB0111523D0 (en) | Chemical compounds | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| MY127126A (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
| UA84271C2 (en) | Formate salt of o-desmethyl-venlafaxine | |
| DE60216233D1 (en) | Carbolinderivate | |
| UA83233C2 (ru) | Замещенный 2-аминотетралин для лечения депрессии | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| MXPA02012076A (es) | Compuestos quimicos. | |
| MXPA02012659A (es) | Derivados de pirazindiona condensados. | |
| DE60205899D1 (en) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| GEP20094801B (en) | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| IL173377A0 (en) | Compounds for the treatment of metabolic disorders | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| CA2412596A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| TW200500068A (en) | Crystalline therapeutic agent | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| SE0101082D0 (sv) | Novel use | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| GB0212410D0 (en) | Organic compounds |